General Rheumatology

Alternative to vaccination proves mettle in French study

Benefits from 3-month online intervention lasted 2 years, but trial lacked control group

Achieving remission and addressing CV risk factors made a big difference in Greek study

Hypothesized, but evidence not as clear until now

Leading adalimumab brand still dominates market, but net spending plummeted

Off-the-shelf drug reduces skin inflammation in animal models and human cell culture

Case-control study reinforces connection between inflammation and HFpEF

Fewer complications and flares occur for those who achieve the target, even intermittently

Genicular artery embolization could help put off the need for knee replacement surgery

Small trial suggests a simpler path to defeat systemic sclerosis

All drugs except one remained more expensive in the U.S.

Some educational materials require college-level reading ability

Not so stomach-safe after all?

It might even help, researchers say